Ocugen, Inc. (OCGN)
After hours:
| Previous close | 2.6800 |
| Open | 2.7500 |
| Bid | 0.0000 x 1100 |
| Ask | 0.0000 x 800 |
| Day's range | 2.6970 - 2.8750 |
| 52-week range | 1.6700 - 17.6500 |
| Volume | |
| Avg. volume | 6,181,170 |
| Market cap | 615.047M |
| Beta (5Y monthly) | 4.21 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.3470 |
| Earnings date | 07 Nov 2022 - 11 Nov 2022 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 7.60 |
- Motley Fool
Here's How This Beaten-Down Stock Could 10X by 2024
On that note, Ocugen (NASDAQ: OCGN) stock is down by more than 65% this year as the small biotech has struggled to commercialize a coronavirus vaccine. To remedy that issue, it's licensing a coronavirus vaccine called Covaxin from Bharat Biotech, an Indian pharmaceutical business. While it's already approved in India, the chances of Ocugen successfully commercializing Covaxin in the U.S. remain a question mark.
- Motley Fool
1 Robinhood Stock to Avoid Right Now
Commission-free trading platform Robinhood Markets grew in prominence helping newer investors participate in what remains one of the best ways to accumulate wealth over time. One example is Ocugen (NASDAQ: OCGN). Can Ocugen succeed in the COVID-19 vaccine market?
- Motley Fool
Ocugen, Inc. (OCGN) Q2 2022 Earnings Call Transcript
Joining me today are Ocugen's chairman and CEO and co-founder, Dr. Shankar Musunuri, who will provide a business update; and our chief accounting officer and senior vice president of finance, Jessica Crespo, who will provide more on our financial results. Earlier this morning, we issued a press release detailing business activity for Q2 2022.
